Incyte's Cash & cash equivalent grew by 11.73 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Incyte's Quick Ratio to 2.32, Quick Ratio remained below Incyte Corporation average.

Within Medical Laboratories industry 14 other companies have achieved higher Quick Ratio than Incyte in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 205 to 1073.

Explain Quick Ratio?
How much Cash & cash equivalents INCY�s has?
What are INCY�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

INCY Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	-13.41 %	-7.43 %	-10.85 %	-4.37 %	23.19 %
Y / Y Cash & cash equivalent Change	78.25 %	83.54 %	38.6 %	34.87 %	-49.57 %
Quick Ratio MRQ	2.32	2.04	1.83	1.53	1.13
INCY's Total Ranking	# 1073	# 205	# 56	# 1139	# 1469
Seq. Current Liabilities Change	-1.99 %	13.53 %	4.7 %	-25.67 %	4.78 %
Seq. Cash & cash equivalent Change	11.73 %	26.18 %	25.58 %	0.68 %	15.04 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 15
Healthcare Sector	# 453
Overall Market	# 1073

Quick Ratio Statistics
High	Average	Low
5.7	3.04	1.03
(Mar 31 2013)		(Dec 31 2024)

Financial Statements
Incyte's Current Liabilities	$ 1,490 Millions	Visit INCY's Balance sheet
Incyte's Cash & cash equivalent	$ 3,461 Millions	Visit INCY's Balance sheet
Source of INCY's Sales		Visit INCY's Sales by Geography

Cumulative Incyte's Quick Ratio

INCY's Quick Ratio for the trailling 12 Months

INCY Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-9.26 %	-0.33 %	7.84 %	18.86 %	25.36 %
Y / Y Cash & cash equivalent TTM Growth	60.12 %	7.88 %	-25.06 %	-41.02 %	-52.58 %
Quick Ratio TTM	1.95	1.61	1.34	1.2	1.1
Total Ranking TTM	# 3864	# 2458	# 1266	# 3079	# 3197
Seq. Current Liabilities TTM Growth	-3.94 %	-2.04 %	-2.65 %	-0.94 %	5.51 %
Seq. Cash & cash equivalent TTM Growth	16.08 %	17.54 %	9.29 %	7.38 %	-21.79 %

Quick ratio ranking by company, industry and sector >> Back to INCY Financial Strength Comparisons >> Go to Compare INCY Quick Ratio to its Competitors

On the trailing twelve months basis INCY Cash & cash equivalent soared by 78.25 % in Q1 2026 year on year, while Current Liabilities decreased to $1,490 millions, this led to increase in in Incyte's Quick Ratio to 1.95, Quick Ratio remained below INCY average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 35 other companies have achieved higher Quick Ratio than Incyte. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2458 to 3864.

Explain Quick Ratio?
How much Cash & cash equivalents INCY�s has?
What are INCY�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 36
Healthcare Sector	# 881
Within the Market	# 3864

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.58	3.02	1.1
(Sep. 30, 2014)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Medical Laboratories Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Personalis Inc	5.97	$ 233.218 Millions	$ 39.045 Millions
Castle Biosciences Inc	5.37	$ 261.685 Millions	$ 48.761 Millions
Veracyte Inc	5.16	$ 263.136 Millions	$ 51.019 Millions
Butterfly Network Inc	5.08	$ 137.954 Millions	$ 27.153 Millions
Guardant Health Inc	3.77	$ 1,102.760 Millions	$ 292.145 Millions
Bionexus Gene Lab Corp	3.30	$ 2.627 Millions	$ 0.797 Millions
Fulgent Genetics Inc	3.07	$ 276.302 Millions	$ 90.134 Millions
Caredx Inc	2.36	$ 187.176 Millions	$ 79.153 Millions
Incyte Corporation	2.32	$ 3,461.114 Millions	$ 1,489.649 Millions
Sera Prognostics Inc	2.02	$ 47.401 Millions	$ 23.419 Millions
Biodesix Inc	1.76	$ 25.572 Millions	$ 14.489 Millions
Exagen Inc	1.71	$ 21.513 Millions	$ 12.564 Millions
Medpace Holdings Inc	1.34	$ 652.681 Millions	$ 488.670 Millions
Bioaffinity Technologies Inc	0.97	$ 3.098 Millions	$ 3.185 Millions
Grail Inc	0.93	$ 69.344 Millions	$ 74.709 Millions
Radnet Inc	0.78	$ 495.794 Millions	$ 635.634 Millions

Date modified: 2026-09-12T06:11:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.